Early, Continuous Ocrelizumab Therapy Reduces Relapsing MS Progression
Early, continuous ocrelizumab was related to a sustained reduction of relapsing MS progression compared with patients who switched from IFN β-1a.
Treatments
P-tau217 Distinguishes Alzheimer Disease From Other Neurodegenerative Diseases
Plasma tau phosphorylated at threonine 217 can be used to accurately differentiate Alzheimer’s disease from other neurodegenerative diseases.
Effects of BMI on B-Cells in Ocrelizumab-Treated Multiple Sclerosis
Researchers confirmed the effectiveness of ocrelizumab in the treatment of relapsing-remitting and progressive MS, and found significant influence of BMI on B-cell repopulation.
Casimersen New Drug Application Submitted for DMD
Sarepta Therapeutics has completed the submission of the casimersen NDA for the treatment of DMD in patients who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
Missed Opportunities for Secondary ASCVD Prevention After Stroke
Uptake of guideline-directed preventive therapies is lower for patients with stroke and peripheral artery disease compared with those with coronary artery disease.
Greater Proportion of RMS Patients Achieve NEDA-3 With Ofatumumab vs Teriflunomide
Treatment with ofatumumab was associated with a greater proportion of patients with relapsing forms of multiple sclerosis achieving no evidence of disease activity, compared with those who received teriflunomide.
Methods for Injecting OnabotulinumtoxinA for Migraine Prevention Vary Between Clinicians
Researchers explored alterations in PREEMPT protocol and the explanations for them using an anonymous questionnaire to headache clinicians.
FDA Grants Fast Track Status to Arimoclomol for ALS
The FDA has granted Fast Track designation to arimoclomol (Orphazyme A/S) for the treatment of amyotrophic lateral sclerosis.
Sublingual Apomorphine Hydrochloride Approved for Off Episodes in Parkinson Disease
This sublingual film formulation of apomorphine was designed for use as a fast-acting, on-demand treatment for all types of motor off episodes.
Unapproved Cannabidiol, Curcumin Injectables Marketed for Multiple Disorders Recalled
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
-
Loading...
-
Loading...
Next post in General Neurology
